Potassium acetate
Identification
- Name
- Potassium acetate
- Accession Number
- DB14498
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Potassium acetate (DB14498)
- Weight
- Average: 98.1423
Monoisotopic: 97.977011201 - Chemical Formula
- C2H3KO2
- Synonyms
- Not Available
Pharmacology
- Indication
Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Target Actions Organism USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
Mostly urine but also skin and feces.
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir Abacavir may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acarbose Acarbose may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acebutolol Acebutolol may increase the hyperkalemic activities of Potassium acetate. Aceclofenac Aceclofenac may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Aclidinium Aclidinium may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acrivastine Acrivastine may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataPotassium Acetate Injection, solution, concentrate 392 mg/1mL Intravenous American Regent 1990-09-30 2014-07-01 US 
Potassium Acetate Injection, solution, concentrate 3.93 g/20mL Intravenous Hospira, Inc. 2014-03-27 Not applicable US Potassium Acetate Injection, solution 196 mg/1mL Intravenous American Regent 1990-09-30 2012-11-29 US Potassium Acetate Injection, solution, concentrate 196.3 mg/1mL Intravenous Hospira, Inc. 2013-12-23 Not applicable US Potassium Acetate Liquid 392 mg Intravenous Sandoz Canada Incorporated 1988-12-31 2016-10-24 Canada 
Potassium Acetate Inj 2meq/ml Solution Intravenous Abbott 1984-12-31 2008-06-06 Canada Potassium Acetate Inj 392mg/ml USP Liquid Intravenous Lyphomed, Division Of Fujisawa Canada Inc. 1984-12-31 1996-09-10 Canada Potassium Acetate Injection Solution Intravenous Fresenius Kabi 1984-12-31 Not applicable Canada Potassium Acetate Injection USP Liquid Intravenous Omega Laboratories Ltd 2016-07-18 Not applicable Canada Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataPotassium Acetate Injection, solution, concentrate 3.93 g/20mL Intravenous Exela Pharma Sciences, LLC 2016-01-07 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aminosyn Potassium acetate (128 mg/100mL) + Alanine (448 mg/100mL) + Arginine (343 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (252 mg/100mL) + L-Lysine acetate (252 mg/100mL) + Leucine (329 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phenylalanine (154 mg/100mL) + Phosphoric acid (40 mg/100mL) + Proline (300 mg/100mL) + Serine (147 mg/100mL) + Sodium chloride (234 mg/100mL) + Threonine (182 mg/100mL) + Tryptophan (56 mg/100mL) + Tyrosine (31 mg/100mL) + Valine (280 mg/100mL) Injection, solution Intravenous Hospira, Inc. 2011-03-23 2017-11-01 US Aminosyn 3.5% M Potassium acetate (128 mg) + Alanine (448 mg) + Arginine (343 mg) + Glycine (448 mg) + Histidine (105 mg) + Isoleucine (252 mg) + L-Lysine acetate (252 mg) + Leucine (329 mg) + Magnesium acetate (21 mg) + Methionine (140 mg) + Phenylalanine (154 mg) + Proline (300 mg) + Serine (147 mg) + Sodium chloride (234 mg) + Threonine (182 mg) + Tryptophan (56 mg) + Tyrosine (31 mg) + Valine (280 mg) Liquid Intravenous Abbott 1980-12-31 1999-08-09 Canada Hyperlyte (multi-electrolyte Concentrate) Potassium acetate (690 mg) + Calcium acetate (440 mg) + Sodium gluconate (1.09 g) + Magnesium acetate (860 mg) + Potassium chloride (2.46 g) + Sodium acetate (2.72 g) Liquid Intravenous B. Braun Medical Inc. 1998-09-04 2017-07-15 Canada Hyperlyte CR Multi-electrolyte Concentrate Potassium acetate (1.96 g) + Calcium chloride (370 mg) + Magnesium chloride (510 mg) + Sodium acetate (680 mg) + Sodium chloride (1.17 g) Liquid Intravenous B. Braun Medical Inc. 1998-09-03 Not applicable Canada Lypholyte Potassium acetate (690 mg) + Calcium acetate (440 mg) + Sodium gluconate (1.1 g) + Magnesium acetate (860 mg) + Potassium chloride (2.5 g) + Sodium acetate (2.7 g) Solution Intravenous Partners Health Care, Inc. 1996-08-14 2008-01-10 Canada Lypholyte Multi-electrolyte Conc Inj Potassium acetate (34.5 mg) + Calcium acetate (22 mg) + Sodium gluconate (55 mg) + Magnesium acetate (43 mg) + Potassium chloride (125 mg) + Sodium acetate (135 mg) Liquid Intravenous Lyphomed, Division Of Fujisawa Canada Inc. 1991-12-31 1996-09-10 Canada Normosol-M & 5% Dextrose Potassium acetate (0.128 g) + Dextrose, unspecified form (5 g) + Magnesium acetate (0.021 g) + Sodium chloride (0.234 g) Solution Intravenous Icu Medical Canada Inc 1965-12-31 Not applicable Canada Normosol-M and Dextrose Potassium acetate (128 mg/100mL) + D-glucose monohydrate (5 g/100mL) + Magnesium acetate (21 mg/100mL) + Sodium chloride (234 mg/100mL) Injection, solution Intravenous Hospira, Inc. 1975-08-13 2021-05-01 US Plasma-lyte 56 Potassium acetate (1.28 mg/1mL) + Magnesium acetate tetrahydrate (.23 mg/1mL) + Sodium chloride (2.34 mg/1mL) Injection Intravenous Baxter Healthcare Corporation 1984-06-15 2007-05-31 US Plasma-lyte 56 5% Dextrose Inj Potassium acetate (128 mg) + Dextrose, unspecified form (5 g) + Magnesium acetate (32 mg) + Sodium chloride (234 mg) Liquid Intravenous Baxter Laboratories 1990-12-31 2014-04-17 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hyperlyte CR Potassium acetate (1.96 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Magnesium chloride hexahydrate (0.51 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL) + Sodium chloride (1.17 g/20mL) Injection, solution, concentrate Intravenous B. Braun Medical Inc. 2012-04-12 Not applicable US Nutrilyte Potassium acetate (34.5 mg/1mL) + Calcium acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-09-30 2013-05-08 US Nutrilyte II Potassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-10-01 2014-01-01 US Nutrilyte II Potassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-10-01 2014-01-01 US Potassium Acetate Potassium acetate (392 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-09-30 2014-07-01 US Potassium Acetate Potassium acetate (196 mg/1mL) Injection, solution Intravenous American Regent 1990-09-30 2012-11-29 US
Categories
- ATC Codes
- B05XA17 — Potassium acetate
- Drug Categories
- Acetates
- Acids, Acyclic
- Agents causing hyperkalemia
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Drugs that are Mainly Renally Excreted
- Electrolyte Solutions
- Fatty Acids
- Fatty Acids, Volatile
- I.V. Solution Additives
- Lipids
- Potassium Compounds
- Potassium Salt
- Replacement Preparations
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Carboxylic acid derivatives
- Direct Parent
- Acetate salts
- Alternative Parents
- Monocarboxylic acids and derivatives / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Acetate salt / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- potassium salt (CHEBI:32029)
Chemical Identifiers
- UNII
- M911911U02
- CAS number
- 127-08-2
- InChI Key
- SCVFZCLFOSHCOH-UHFFFAOYSA-M
- InChI
- InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
- IUPAC Name
- potassium acetate
- SMILES
- [K+].CC([O-])=O
References
- General References
- Not Available
- External Links
- KEGG Compound
- C12554
- ChemSpider
- 29104
- ChEBI
- 32029
- ChEMBL
- CHEMBL1201058
- Wikipedia
- Potassium_acetate
- AHFS Codes
- 40:12.00 — Replacement Preparations
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Illness, Critical 1 2 Completed Treatment Acute Heart Failure (AHF) / Decompensated Heart Failure / Heart Failure 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous 10.5 g/1000ml Solution Intravenous 2.453 g Injection, solution Intracardiac 16 mmol/20mL Solution Oral 12.27 g/100mL Injection, solution Intravenous 2.34 g/L Injection, solution Intravenous 2.34 g/1000ml Injection, solution Intravenous 5.26 g/L Injection, solution Intravenous 3.38 g Injection, solution Intravenous 3.38 g/1000ml Injection, emulsion Intravenous 1.17 g Injection, emulsion Intravenous 1.56 g Injection, emulsion Intravenous 1.755 g Injection, emulsion Intravenous 2.34 g Injection, emulsion Intravenous 3.12 g Injection, emulsion Intravenous 3.51 g Injection, emulsion Intravenous 4.68 g Solution Intravenous Injection, emulsion Parenteral 2.33 g Injection, emulsion Intravenous 1.03 g Injection, emulsion Intravenous 1.83 g Emulsion Intravenous 1.83 g Injection Intravenous 1.03 g Emulsion Intravenous 20 mg Emulsion Intravenous 16 g Injection, emulsion Intravenous 3.88 g/1000ml Emulsion Parenteral 20 g/l Emulsion Parenteral 3.88 g Emulsion Intravenous 88 g Injection, emulsion Intravenous 120 g Injection, emulsion Intravenous 160 g Injection, emulsion Intravenous 4.66 g/1000ml Emulsion Parenteral 1.872 g/l Emulsion Parenteral 0.222 g Injection, emulsion Intravenous 150 g Injection, emulsion Intravenous 225 g Injection, emulsion Intravenous 300 g Emulsion Parenteral 6.792 g/l Emulsion Intravenous 6.792 mg Emulsion Intravenous 150 g Emulsion Intravenous 225 g Emulsion Parenteral 2.4 g/l Emulsion Parenteral 2.88 g/l Injection, emulsion Intravenous 5.82 g/1250ml Emulsion Intravenous 4.656 g Emulsion Parenteral 6.792 g Injection, emulsion Intravenous 4.25 g/625ml Emulsion Intravenous 6.792 g Injection, solution, concentrate Intravenous Injection, emulsion Intravenous 120 g/1875ml Injection, emulsion Intravenous 160 g/2500ml Injection, emulsion Intravenous 80 g/1250ml Injection, emulsion Intravenous 150 g/1250ml Injection, emulsion Intravenous 225 g/1875ml Injection, emulsion Intravenous 300 g/2500ml Injection, emulsion Intravenous 180 g/1250ml Injection, emulsion Intravenous 270 g/1875ml Injection, emulsion Intravenous 360 g/2500ml Injection, emulsion Intravenous 11.64 g/2500ml Injection, emulsion Intravenous 8.73 g/1875ml Injection, emulsion Intravenous 90 g/625ml Injection Intravenous Liquid Intravenous Injection, solution Intravenous Injection, solution Parenteral 3 MEQ/ML Injection, solution, concentrate Intravenous 3 MEQ/ML Injection, solution Intravenous 196 mg/1mL Injection, solution, concentrate Intravenous 1.47 g/100mL Injection, solution, concentrate Intravenous 196.3 mg/1mL Injection, solution, concentrate Intravenous 3.93 g/20mL Injection, solution, concentrate Intravenous 392 mg/1mL Liquid Intravenous 392 mg Injection, solution Intravenous 29.4 g/100mL Solution Intravenous Liquid Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 342.0 mg/mL ALOGPS logP -0.27 ALOGPS logP -0.22 ChemAxon logS 0.54 ALOGPS pKa (Strongest Acidic) 4.54 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 40.13 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 23.48 m3·mol-1 ChemAxon Polarizability 4.96 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [PubMed:17334838]
- Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [PubMed:17347782]
- Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [PubMed:17366541]
- Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [PubMed:17369284]
- Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [PubMed:17444965]
Drug created on July 11, 2018 10:28 / Updated on January 25, 2021 22:38